In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

数据表明， 早在治疗14天时即可观察到Fabhalta可减少C3G患者的蛋白尿，此结果具临床意义并持续至12个月。 在研究的开放标签阶段，切换至Fabhalta的受试者也表现出蛋白尿的减少。

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

全球与中国司库奇尤单抗注射液市场运营态势及前景预测研究报告2024-2030年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 2.1 全球司库奇尤单抗注射液总体市场规模：2023 VS 2030 ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...